Company Encyclopedia
View More
name
Imunon
IMNN.US
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines. The company’s lead clinical program is IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response.
1.945 T
IMNN.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Imunon, Inc. Faces Market Volatility: The Impact of Short Selling on Stock Prices

    Imunon, Inc. (IMNN) faces market volatility due to short selling, which may lead to temporary and long-term stock price declines. The company cannot predict future stock issuances' impact on market price or short selling activities. Large sales or perceived sales could adversely affect stock value. The average stock price target is $12.00, indicating a 184.36% upside potential.

    Tip Ranks·
    US
    IMNN
    0.00%
    Tip Ranks·
    US
    IMNN
    0.00%

    Alliance Global Partners Remains a Buy on Imunon (IMNN)

    Alliance Global Partners' analyst James Molloy reiterated a Buy rating on Imunon with a $12.00 price target. Molloy, who covers the Healthcare sector, has an average return of -22.9% and a 23.81% success rate. The general consensus on The Street is a Moderate Buy for Imunon, also with a $12.00 average price target.

    Tip Ranks·
    US
    IMNN
    0.00%
    Tip Ranks·
    US
    IMNN
    0.00%

    IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update

    R&D Day showcased remarkable Investigator optimism, continued strengthening supportive data, and significant progress with Phase 3 OVATION 3 Study in pursuit of first frontline immunotherapy for advanced ovarian cancer ...

    GlobeNewswire·
    US
    IMNN
    0.00%
    GlobeNewswire·
    US
    IMNN
    0.00%

    Imunon | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    IMNN
    0.00%
    LB filings·
    US
    IMNN
    0.00%

    Imunon | 8-K: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    IMNN
    0.00%
    LB filings·
    US
    IMNN
    0.00%
    © 2025 Longbridge｜Disclaimer